Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25775975 | 0.74 | HPGD (0.44) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL25775977 | 0.74 | HSD17B10 (0.47) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL25780148 | 0.71 | HPGD (0.41) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL2321756 | 0.69 | L3MBTL1 (0.44) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL22554301 | 0.69 | HPGD (0.46) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL14883466 | 0.68 | APP (0.46) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL12354238 | 0.68 | HSD17B10 (0.49) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL31347189 | 0.68 | DGAT1 (0.36) | HSD17B10HPGDHTTMAPT | |
| SCHEMBL20508589 | 0.67 | HSD17B10 (0.47) | HSD17B10HPGDHTTLMNAKMT2A | |
| SCHEMBL25780241 | 0.66 | MYC (0.37) | HSD17B10HPGDHTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | HSD17B10 3839/4885HPGD 3902/4885HTT 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.